Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients

Vanessa Torres-Llenza, Pooja Lakshmin, Daniel Z Lieberman Department of Psychiatry and Behavioral Sciences, George Washington University School of Medicine and Health Sciences, Washington, DC, USA Abstract: The lack of long-term medication adherence is a challenge in the treatment of bipolar disor...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Torres-Llenza V, Lakshmin P, Lieberman DZ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	antipsychotic adherence partial agonist mood stabilizer review Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/32300931ddf0438fac7680092d79a3f0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:32300931ddf0438fac7680092d79a3f0
record_format	dspace
spelling	oai:doaj.org-article:32300931ddf0438fac7680092d79a3f02021-12-02T00:51:05ZSpotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients1178-2021https://doaj.org/article/32300931ddf0438fac7680092d79a3f02018-01-01T00:00:00Zhttps://www.dovepress.com/spotlight-on-once-monthly-long-acting-injectable-aripiprazole-and-its--peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Vanessa Torres-Llenza, Pooja Lakshmin, Daniel Z Lieberman Department of Psychiatry and Behavioral Sciences, George Washington University School of Medicine and Health Sciences, Washington, DC, USA Abstract: The lack of long-term medication adherence is a challenge in the treatment of bipolar disorder, particularly during the maintenance phase when symptoms are less prominent. The rate of nonadherence is ~20%–60% depending on how strict a definition is used. Nonadherence worsens the course of bipolar disorder and can add hundreds of thousands of dollars to the lifetime cost of treating the illness. Long-acting injectable (LAI) medication is an attractive alternative to daily dosing of oral medication, especially among patients who are ambivalent about treatment. The purpose of this paper is to review the evidence for the safety and efficacy of LAI aripiprazole, which was recently approved for the treatment of bipolar disorder. The approval was based on a single double-blind, placebo-controlled, multisite trial that recruited participants from 103 sites in 7 countries. A total of 731 participants with bipolar disorder were enrolled in the study. Out of that total, 266 were successfully stabilized on LAI aripiprazole and entered the randomization phase. Treatment-emergent adverse events were, for the most part, mild to moderate. Akathisia was the most common adverse event, which, combined with restlessness, was experienced by 23% of the sample. At the end of the 52-week study period, nearly twice as many LAI-treated participants remained stable compared to those treated with placebo. Stability during the maintenance phase is arguably the most important goal of treatment. It is during this period of relative freedom from symptoms that patients are able to build a meaningful and satisfying life. The availability of a new treatment agent, particularly one that has the potential to enhance long-term adherence, is a welcome development. Keywords: antipsychotic, adherence, partial agonist, mood stabilizer, reviewTorres-Llenza VLakshmin PLieberman DZDove Medical Pressarticleantipsychoticadherencepartial agonistmood stabilizerreviewNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 14, Pp 285-292 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	antipsychotic adherence partial agonist mood stabilizer review Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	antipsychotic adherence partial agonist mood stabilizer review Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Torres-Llenza V Lakshmin P Lieberman DZ Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients
description	Vanessa Torres-Llenza, Pooja Lakshmin, Daniel Z Lieberman Department of Psychiatry and Behavioral Sciences, George Washington University School of Medicine and Health Sciences, Washington, DC, USA Abstract: The lack of long-term medication adherence is a challenge in the treatment of bipolar disorder, particularly during the maintenance phase when symptoms are less prominent. The rate of nonadherence is ~20%–60% depending on how strict a definition is used. Nonadherence worsens the course of bipolar disorder and can add hundreds of thousands of dollars to the lifetime cost of treating the illness. Long-acting injectable (LAI) medication is an attractive alternative to daily dosing of oral medication, especially among patients who are ambivalent about treatment. The purpose of this paper is to review the evidence for the safety and efficacy of LAI aripiprazole, which was recently approved for the treatment of bipolar disorder. The approval was based on a single double-blind, placebo-controlled, multisite trial that recruited participants from 103 sites in 7 countries. A total of 731 participants with bipolar disorder were enrolled in the study. Out of that total, 266 were successfully stabilized on LAI aripiprazole and entered the randomization phase. Treatment-emergent adverse events were, for the most part, mild to moderate. Akathisia was the most common adverse event, which, combined with restlessness, was experienced by 23% of the sample. At the end of the 52-week study period, nearly twice as many LAI-treated participants remained stable compared to those treated with placebo. Stability during the maintenance phase is arguably the most important goal of treatment. It is during this period of relative freedom from symptoms that patients are able to build a meaningful and satisfying life. The availability of a new treatment agent, particularly one that has the potential to enhance long-term adherence, is a welcome development. Keywords: antipsychotic, adherence, partial agonist, mood stabilizer, review
format	article
author	Torres-Llenza V Lakshmin P Lieberman DZ
author_facet	Torres-Llenza V Lakshmin P Lieberman DZ
author_sort	Torres-Llenza V
title	Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients
title_short	Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients
title_full	Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients
title_fullStr	Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients
title_full_unstemmed	Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients
title_sort	spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar i disorder in adult patients
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/32300931ddf0438fac7680092d79a3f0
work_keys_str_mv	AT torresllenzav spotlightononcemonthlylongactinginjectablearipiprazoleanditspotentialasmaintenancetreatmentforbipolaridisorderinadultpatients AT lakshminp spotlightononcemonthlylongactinginjectablearipiprazoleanditspotentialasmaintenancetreatmentforbipolaridisorderinadultpatients AT liebermandz spotlightononcemonthlylongactinginjectablearipiprazoleanditspotentialasmaintenancetreatmentforbipolaridisorderinadultpatients
_version_	1718403429548687360

Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients

Ejemplares similares